DiaSorin Company Research & Development Immunodiagnostic Solutions Molecular Solutions People Culture Investor Relations DiaSorin scientific contribution at ECCMID Amsterdam 2016 11/03/2016 Tuesday, April 12 Toxoplasma gondii, cytomegalovirus and Treponema pallidum infection in pregnancy, what's new? Allegati Invitation Immunodiagnostic Solutions Clinical Areas Systems Committed to efficiency News Events Catalog Dialog Contacts Search form Search English Italiano DiaSorin S.p.A. - Share Capital € 55.948.257 R.E.A. 180729 Fiscal Code and Subscription to Vercelli Companies Register no 13144290155 Legal Notices Privacy Policy Modern Slavery Act Statement Scroll down ▼ close Android Iphone

DiaSorin Company Research & Development Immunodiagnostic Solutions Molecular Solutions People Culture Investor Relations Research & Development Immunodiagnostics Clinical Areas Enter http://www.diasorin.com/en/research-development/clinical-areas Immunodiagnostics Technology and Innovation Enter http://www.diasorin.com/en/research-development/immunodiagnostics/reagents Publications Immunodiagnostics Papers and posters Browse and download http://www.diasorin.com/en/research-development/immunodiagnostics/papers About Us Our R&D mission Regularly delivering high quality and innovative tests to fuel product pipeline http://www.diasorin.com/en/research-development/about-us/rd-data-and-investment Immunodiagnostics R&D sites Enter http://www.diasorin.com/en/research-development/immunodiagnostics/rd-sites Research & Development Immunodiagnostics About Us Contacts Search form Search English Italiano DiaSorin S.p.A. - Share Capital € 55.948.257 R.E.A. 180729 Fiscal Code and Subscription to Vercelli Companies Register no 13144290155 Legal Notices Privacy Policy Modern Slavery Act Statement Scroll down ▼ close Android Iphone